Quietly but unambiguously, pharma firms are accelerating their diversification away from China and are now looking to other emerging markets for growth, a strategy that reflects increasing pressures from China's volume-based procurement scheme but also US-China tensions and other geopolitical risks.

Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.

Leadership succession is proceeding within South Korean pharmaceutical corporations such as Daiichi Sankyo Korea, Astellas Pharma Korea, Kyowa Kirin Korea as well as MSD Korea.

Esepapogene zalarnarepvec, BJT-778 and pegozafermin are the latest investigational products that the European Medicines Agency said merited a place on its priority medicines scheme.